Factors relating to neurotoxicity of artemisinin antimalarial drugs "listening to arteether".
The discovery of the occult brainstem neurotoxicity subsequent to widespread deployment of artemisinin derivatives has created particular problems. That is, the clinical setting for artemisinin use is problematic for accomplishing what ordinarily would be addressed in phase I-II clinical trials. Nevertheless, it is clear that an urgent and vital need exists for the deployment and widespread availability of artemisinins. The work done to date has already yielded a substantial body of evidence that, while incomplete, provides guidelines for artemisinin use to minimize the risk of these drugs while preserving their much-needed efficacy. The evidence thus far shows that route of administration, oil/water solubility and concentration-duration of drug level, are critical determinants of toxicity and can be given appropriate consideration in the clinical decisions regarding route, choice of drug used, and drug regimens. In this regard, an oral, water-soluble drug with moderately rapid clearance may be the most attractive choice in the absence of significant differences in efficacy. The same body of evidence clearly shows that toxicity can, and does, develop with no obvious or useful clinical marker. Therefore, the development and validation of a test that can reliably detect the onset of injury, at a reversible stage, is a critical path task for any future development in this class. More complete understanding of mechanisms, kinetics, and molecular targets of neurotoxicity, will certainly be forthcoming. A continuing, more generalized use of these drugs, however, cannot be fully endorsed without a useful, practical clinical test of toxicity. The requirement is especially critical in light of the reality that those patients receiving artemisinin derivatives live in high risk environments and are likely to receive repeated courses of therapy with little likelihood of close, post marketing surveillance.
Brewer
T G
TG
Armed Forces Research Institute of Medical Sciences, APO, AP 96546, USA. brewer@wrair-emhl.army.mil
Genovese
R F
RF
Newman
D B
DB
Li
Q
Q
D000284:Administration, Oral; D000818:Animals; D000962:Antimalarials / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D037621:Artemisinins; D001927:Brain Diseases / Q000139:chemically induced* / Q000175:diagnosis; D001933:Brain Stem; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D016903:Drug Monitoring; D006801:Humans; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D012717:Sesquiterpenes / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D012995:Solubility; D013997:Time Factors
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; C031327:artemisinin; C055141:artemotil